hit counter
GBS Inc. (GBS) Stock News Sentiment & Price - Sentifly
GBS - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



GBS Inc. (GBS)

USA
Medical Instruments & Supplies
NASDAQ
GBS Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
GBS Latest news
Seeking Alpha
Neutral
GBS Inc. (GBS) CEO Steven Boyages on Q1 2022 Results - Earnings Call Transcript
2021-11-11 20:44

GBS Inc. (GBS) CEO Steven Boyages on Q1 2022 Results - Earnings Call Transcript

GlobeNewsWire
Neutral
GBS Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights
2021-11-11 16:05

– Announced Pre-Submission Package sent to the FDA for its Glucose Biosensor Test –

GlobeNewsWire
Neutral
GBS Inc. to Present First Quarter 2022 Financial Results and Recent Corporate Update on November 11
2021-11-01 16:05

Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET

GlobeNewsWire
Neutral
GBS Inc. Announces Executive Leadership Changes to Accelerate Product Development and Manufacturing
2021-11-01 08:00

NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced changes to its executive leadership team as the Company advances into a new phase focused on product development and planned manufacturing.

PRNewsWire
Neutral
FDA Pre-Submission for Saliva-Based Glucose Test to Replace Invasive Finger-Prick
2021-10-19 03:01

SYDNEY, Oct. 19, 2021 /PRNewswire/ -- The iQ Group Global Ltd (NSX.IQG), on behalf of its subsidiary, Life Science Biosensor Diagnostics Pty Ltd (LSBD), is pleased to announce that one of its licensees, GBS Inc (Nasdaq: GBS); a life sciences company operating in the Asia Pacific region, under license from LSBD, to commercialize its non-invasive, real-time Glucose Salivary test; has filed a Pre-Submission package with the United States (US) Food and Drug Administration (FDA). The purpose of this Pre-Submission is to confirm with the FDA the clinical trial design, including trial objectives.

GlobeNewsWire
Neutral
GBS Inc. Announces its Pre-Submission package is with the FDA
2021-10-13 08:30

NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it has filed a Pre-Submission package with the United States (US) Food and Drug Administration (FDA). The purpose of this pre-submission is to confirm with the FDA that GBS is following the proper steps to conduct the clinical studies enabling it to develop the glucose biosensor according to the FDA regulatory standards.

GlobeNewsWire
Neutral
GBS Inc. to Present at Upcoming September Virtual Investor Conferences
2021-09-07 16:05

H.C. Wainwright 23 rd Global Investor Conference: September 13 th - 15 th

Pulse2
Positive
GBS Stock: Over 40% Increase Pre-Market Explanation
2021-09-01 06:59

The stock price of GBS Inc (NASDAQ: GBS) increased by over 40% pre-market. These are some details you should know.

Seeking Alpha
Neutral
GBS Inc.: Can Its Technology Come Through?
2021-08-31 14:24

GBS is a biotechnology company aiming to utilize saliva as a medium for developing non-invasive diagnostic tests. The companies pipeline products are targeting both the COVID-19 and Diabetes markets.

Benzinga
Positive
Life Sciences Company GBS Develops Technology to Take the Fear out of Diabetes and COVID Testing
2021-08-17 12:02

GBS Inc. is presenting at the Benzinga Healthcare Small Cap Conference on September 29, 2021. For some people with diabetes, testing with a pinprick is no more than a minor inconvenience.

Loading more news...